XML 39 R23.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Intangible Assets and Goodwill (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets and Goodwill |
(Dollars in Millions) |  | September 30, 2018 |  | December 31, 2017
Intangible assets with definite lives: |  |  |  |
Patents and trademarks — gross |  | $ | 35,478 |  |  | 36,427 |
Less accumulated amortization |  | 9,077 |  |  | 7,223 |
Patents and trademarks — net (1) |  | 26,401 |  |  | 29,204 |
Customer relationships and other intangibles — gross |  | 21,176 |  |  | 20,204 |
Less accumulated amortization |  | 8,168 |  |  | 7,463 |
Customer relationships and other intangibles — net |  | 13,008 |  |  | 12,741 |
Intangible assets with indefinite lives: |  |  |  |
Trademarks |  | 7,002 |  |  | 7,082 |
Purchased in-process research and development (2) |  | 2,226 |  |  | 4,201 |
Total intangible assets with indefinite lives |  | 9,228 |  |  | 11,283 |
Total intangible assets — net |  | $ | 48,637 |  |  | 53,228 |
(1) Net of approximately $0.1 billion classified as assets held for sale on the Consolidated Balance Sheet related to the divestiture of the LifeScan business, which was pending as of September 30, 2018. See Note 10 to the Consolidated Financial Statements for additional details (2) The decrease was primarily attributable to the write-down of $1.1 billion related to the assets acquired in the acquisitions of Alios Biopharma Inc. (Alios) and XO1 Limited (XO1). Of the $1.1 billion, the Company recorded a partial impairment charge of $0.8 billion related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios. The impairment charge was calculated based on updated cash flow projections discounted for the inherent risk in the asset development and reflects the impact of recent phase 2b clinical trial suspension, a decrease in the probability of success factors and the ongoing analysis of asset development activities. In addition, an impairment charge of $0.3 billion was recorded for the discontinuation of the development project for an anti-thrombin antibody associated with the 2015 acquisition of XO1.
Goodwill | Goodwill as of September 30, 2018 was allocated by segment of business as follows:
(Dollars in Millions) |  | Consumer |  | Pharm |  | Med Devices |  | Total
Goodwill, net at December 31, 2017 |  | $ | 8,875 |  |  | 9,109 |  |  | 13,922 |  |  | 31,906 |
Goodwill, related to acquisitions |  | 169 |  |  | 51 |  |  | 208 |  |  | 428 |
Goodwill, related to divestitures |  | — |  |  | — |  |  | (1,246 | ) | (1) | (1,246 | )
Currency translation/Other |  | (304 | ) |  | (48 | ) |  | (34 | ) |  | (386 | )
Goodwill, net at September 30, 2018 |  | $ | 8,740 |  |  | 9,112 |  |  | 12,850 |  |  | 30,702 |
(1) Goodwill of $1.0 billion is related to the divestiture of the LifeScan business and $0.2 billion is related to the divestiture of the Advanced Sterilization Products business, both of which were pending and classified as assets held for sale on the Consolidated Balance Sheet as of September 30, 2018.

X
- Definition Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block] + References No definition available. + Details
Name: | jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
Namespace Prefix: | jnj_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267 + Details
Name: | us-gaap_ScheduleOfGoodwillTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration